How to Get Tresiba in New Jersey

What Is Tresiba and Why Do Physicians Prescribe It in New Jersey?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours at steady state. Novo Nordisk received FDA approval in September 2015 for adults and pediatric patients (age 1 and older) with type 1 or type 2 diabetes [1]. Its flat pharmacokinetic profile produces lower day-to-day glucose variability than insulin glargine U-100, which is why many New Jersey endocrinologists favor it for patients with unpredictable schedules or frequent nocturnal hypoglycemia.

The DEVOTE cardiovascular outcomes trial (N=7,637) published in the New England Journal of Medicine demonstrated that degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE) and produced 40% fewer severe hypoglycemic episodes (rate ratio 0.60; 95% CI 0.48-0.76; P<0.001 for superiority) [2]. That hypoglycemia advantage is the most cited reason clinicians in New Jersey choose degludec over older basal insulins.

The American Diabetes Association's 2024 Standards of Care classify basal insulin analogs, including degludec, as preferred over NPH insulin for most patients with type 2 diabetes who require basal therapy, specifically noting lower nocturnal hypoglycemia risk [3]. New Jersey has approximately 880,000 adults living with diagnosed diabetes, according to CDC surveillance data [4], making access to modern basal insulins a meaningful public-health question.

New Jersey Telehealth Rules for Prescribing Tresiba

New Jersey actively permits telehealth prescribing of controlled and non-controlled medications, including insulin degludec, provided the prescriber establishes a valid patient-provider relationship. Tresiba is not a controlled substance, so the requirements are straightforward: a licensed NJ provider, a documented clinical encounter (synchronous video or audio-video meeting qualifies), and a prescription issued through a DEA-registered or NJ-licensed prescriber.

New Jersey's telemedicine statute (N.J.S.A. 45:1-61 through 45:1-67) requires that telehealth providers use a platform meeting HIPAA security standards and that they comply with the same standard of care as in-person visits [5]. A prescriber physically located outside New Jersey must hold an active NJ license or qualify under the Interstate Medical Licensure Compact, of which New Jersey is a member state [6].

Practical steps for a telehealth Tresiba visit in NJ:

1. Schedule a video appointment with a licensed NJ provider or an IMLC-participating telehealth service.
2. Upload recent lab work (HbA1c drawn within 90 days is standard at most telehealth platforms) and a list of current medications.
3. Attend the synchronous video visit. The provider will review glucose logs, current basal insulin, injection technique, and hypoglycemia history.
4. Receive the electronic prescription (e-Rx) sent directly to your preferred NJ pharmacy or a mail-order pharmacy licensed in New Jersey.

Most established telehealth platforms complete the prescription transmission within hours of the visit. Patients who already have a current Tresiba prescription from another state can request that their NJ-licensed telehealth provider cosign a new prescription; this avoids a gap in therapy.

Who Can Prescribe Tresiba in New Jersey?

Four categories of licensed clinicians in New Jersey can legally issue a Tresiba prescription. Physicians (MD or DO) have full independent prescribing authority under N.J.S.A. 45:9-1. Nurse practitioners (APNs) in New Jersey have had full practice authority since 2022 under the Nurse Practice Act amendments, meaning they no longer require a collaborative agreement with a physician to prescribe [7]. Physician assistants (PAs) may prescribe under a written delegation agreement with a supervising physician, per N.J.S.A. 45:9-27.10 [8]. Certified nurse midwives may prescribe medications within their scope of practice, which typically includes insulin management in patients with gestational diabetes.

Endocrinologists remain the specialists most commonly managing type 1 diabetes with degludec. Primary care physicians and internal medicine physicians handle the large majority of type 2 diabetes prescriptions. A 2023 JAMA Internal Medicine analysis found that 68% of basal insulin prescriptions in the United States originate from primary care clinicians rather than specialists [9], and the pattern in New Jersey mirrors that national figure.

What Labs Are Required Before Starting Tresiba in New Jersey?

No single national guideline mandates a fixed lab panel before initiating insulin degludec, but standard clinical practice in New Jersey aligns with ADA recommendations for baseline diabetes monitoring [3]. The following labs are routinely ordered:

• HbA1c: Establishes glycemic baseline and confirms the diabetes diagnosis. The ADA targets HbA1c <7.0% for most non-pregnant adults, with individualized targets for older adults or those with hypoglycemia unawareness [3].
• Fasting plasma glucose: Documents current fasting glycemia for dose titration.
• Basic metabolic panel (BMP): Renal function (eGFR, serum creatinine) affects osmotic symptoms and is relevant because hyperglycemia-induced dehydration can alter insulin sensitivity; also checks potassium, which may shift with insulin initiation [10].
• Body weight and BMI: Required for weight-based dosing calculations, particularly in type 1 diabetes.
• Lipid panel: Often drawn at the same visit per ADA annual monitoring standards [3].
• Thyroid function (TSH): Recommended for type 1 diabetes patients annually per ADA guidelines [3].
• Urine albumin-to-creatinine ratio: ADA 2024 recommends annual screening for diabetic kidney disease in all patients with diabetes [3].

Most telehealth platforms operating in New Jersey accept lab results from Quest Diagnostics, LabCorp, or any CLIA-certified laboratory. Results must generally be dated within 90 days for a new-patient telehealth visit, though some platforms accept results up to 12 months old for established patients simply renewing a basal insulin prescription.

How Prior Authorization for Tresiba Works in New Jersey

Prior authorization (PA) is required by most New Jersey commercial insurers and by NJ FamilyCare (Medicaid) before Tresiba will be covered at preferred cost-sharing tiers. The PA process in New Jersey typically follows this sequence, though insurer-specific requirements vary.

Step-therapy requirements: Many NJ commercial plans require documented failure of at least one older basal insulin analog, most often insulin glargine U-100 (Lantus/Basaglar) or insulin glargine U-300 (Toujeo), before approving degludec. The prescriber must document that the patient either experienced inadequate glycemic control or clinically significant hypoglycemia on those agents [11].

Documentation the prescriber submits: Current HbA1c, diagnosis code (E10.x for type 1, E11.x for type 2), documentation of step-therapy failure or a medical exception (e.g., severe hypoglycemia unawareness), and the requested dose and frequency.

NJ FamilyCare (Medicaid): Insulin degludec is listed on the NJ FamilyCare preferred drug list with a prior authorization requirement for both type 1 and type 2 diabetes [12]. The state's PA criteria require documentation of hypoglycemia on alternative agents or a clinical reason the patient cannot use a preferred formulary insulin. Approval turnaround is typically 3-5 business days for standard PA and 24-72 hours for urgent PA requests.

Appeals: If PA is denied, the prescriber may file a Level 1 appeal with clinical documentation. New Jersey's Insurance Commissioner regulations require insurers to respond to standard utilization review decisions within 3 business days and urgent decisions within 24 hours [13].

The Novo Nordisk patient assistance program, NovoCare, offers a $35/month co-pay card for commercially insured patients and a free medication program for uninsured patients meeting income criteria [14]. Patients should request this information directly from Novo Nordisk or confirm eligibility through the HealthRX care coordination team.

Tresiba Pharmacy Access in New Jersey

New Jersey has more than 2,800 licensed retail pharmacies, including major chains (CVS, Walgreens, Rite Aid, ShopRite Pharmacy, Walmart Pharmacy) and independent pharmacies. All are authorized to dispense insulin degludec once a valid prescription is received. The drug is stocked as a Schedule II (insulin is not a controlled substance) standard item at most pharmacies in 100 units/mL concentration; the 200 units/mL (U-200) formulation is less consistently stocked and may require 24-48 hours for special order.

Mail-order pharmacies: Patients with NJ FamilyCare or commercial plans may use mail-order pharmacies (e.g., CVS Caremark, Express Scripts, OptumRx) licensed to ship to New Jersey. A 90-day supply through mail order typically costs less out-of-pocket than three separate 30-day retail fills.

503A compounding pharmacies in NJ: A 503A compounding pharmacy may compound preparations that are not commercially available or that are needed for a specific patient need (e.g., altered concentration). Insulin degludec is commercially available in two concentrations and is not on the FDA's list of drugs eligible for compounding under section 503A of the FDCA [15]. Licensed NJ 503A pharmacies therefore cannot legally compound insulin degludec as a copy of Tresiba. Patients should be cautious about any compounding pharmacy offering "compounded degludec" and should ask their prescriber or pharmacist to verify legality under federal and NJ Board of Pharmacy rules [16].

Typical fulfillment timeline: E-prescriptions sent during pharmacy business hours are generally available for same-day pickup at retail pharmacies. Mail-order prescriptions typically arrive within 3-7 business days for standard shipping and 1-2 business days for expedited delivery.

Dosing Tresiba: What New Jersey Patients Should Know

Tresiba is dosed once daily at any time of day, with the same time preferred but with flexibility to shift the dose up to 8 hours in either direction if needed [1]. This flexibility is clinically relevant for shift workers and travelers, two populations well represented in New Jersey's economy.

Starting doses recommended in the FDA label for insulin-naive type 2 diabetes patients are 10 units once daily or one-third to one-half of the total daily insulin dose when converting from another basal insulin [1]. Type 1 diabetes patients typically start at 80% of their previous total basal dose and adjust the bolus insulin separately. The ADA's 2024 consensus report on insulin therapy recommends titrating the basal dose by 2 units every 3 days based on fasting glucose readings, targeting fasting values of 80-130 mg/dL [3].

The SWITCH 2 trial (N=721) published in the Lancet showed that patients with type 2 diabetes who transferred from insulin glargine U-100 to insulin degludec achieved a statistically significant reduction in overall symptomatic hypoglycemia (rate ratio 0.70; 95% CI 0.61-0.80; P<0.001) without worsening HbA1c [17]. That trial enrolled patients specifically selected for hypoglycemia risk, a group common in New Jersey's older diabetic population.

Injection technique matters as much as dose. Degludec should be injected subcutaneously into the abdomen, thigh, or upper arm, rotating sites within the same region to reduce lipohypertrophy [1]. The American Association of Clinical Endocrinology recommends insulin injection site rotation training as a standard component of diabetes self-management education [18].

Transferring a Tresiba Prescription to New Jersey

Patients moving to or within New Jersey can transfer an existing Tresiba prescription under standard pharmacy transfer rules. New Jersey law permits the transfer of non-controlled prescriptions between licensed pharmacies. The receiving NJ pharmacy contacts the dispensing pharmacy, and the transfer is documented per N.J.A.C. 13:39-7.9.

If the original prescriber is not licensed in New Jersey, the transferred prescription remains valid for one fill at the new pharmacy, after which the patient needs a new prescription from an NJ-licensed provider. Patients relocating from another state should plan ahead: schedule a telehealth visit with an NJ-licensed provider before their supply runs out so the new prescription overlaps with the transfer fill.

Patients who used a different basal insulin in another state and wish to switch to Tresiba in New Jersey should request a new visit rather than a simple transfer, because the change requires clinical evaluation and, for insured patients, a fresh prior authorization.

Costs Without Insurance in New Jersey

Without insurance, a 5-pack of Tresiba FlexTouch pens (5 x 3 mL at 100 units/mL, total 1,500 units) carries a list price between $300 and $450 at most New Jersey retail pharmacies as of mid-2025. GoodRx and similar discount programs may reduce this to approximately $260-$320 depending on the pharmacy and the coupon presented.

Novo Nordisk's Insulin Affordability Programs include a cap of $35/month for commercially insured patients using the NovoCare savings card and a Patient Assistance Program providing free insulin to uninsured patients with household income at or below 400% of the federal poverty level [14]. The Medicare Part D senior savings model, now replaced by the $35/month insulin cap mandated by the Inflation Reduction Act for Part D enrollees effective January 2023, limits out-of-pocket insulin costs to $35 per month for all Medicare beneficiaries regardless of plan phase [19].

Monitoring After Starting Tresiba in New Jersey

Once Tresiba is initiated, standard monitoring includes fasting self-monitored blood glucose (SMBG) daily, HbA1c every 3 months until the target is reached and then every 6 months at steady state, and periodic reassessment of injection sites. Continuous glucose monitoring (CGM) is an option covered by most NJ commercial insurers and by NJ FamilyCare for patients with type 1 diabetes and for type 2 diabetes patients using basal-bolus or intensive insulin regimens [20].

The ADA 2024 Standards of Care state: "Most individuals with diabetes who are capable of self-monitoring should perform SMBG as directed by their health care provider, integrated with CGM where feasible" [3]. For patients on basal insulin alone, once-daily fasting SMBG is the minimum for safe titration.

Severe hypoglycemia (glucose <54 mg/dL with cognitive impairment requiring assistance) should prompt an urgent call to the prescribing provider. DEVOTE data showed the annualized rate of severe hypoglycemia with degludec was 0.20 events per patient-year vs. 0.35 with glargine U-100 [2], but the risk is not zero. Patients and caregivers should receive glucagon training before starting any basal insulin.